Norwood Financial’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
$76.5K Hold
355
0.11% 136
2023
Q4
$91.9K Sell
355
-30
-8% -$7.37K 0.14% 110
2023
Q3
$98.9K Buy
385
+10
+3% +$2.67K 0.16% 100
2023
Q2
$107K Sell
375
-30
-7% -$8.93K 0.16% 97
2023
Q1
$113K Hold
405
0.18% 94
2022
Q4
$112K Sell
405
-10
-2% -$2.82K 0.18% 91
2022
Q3
$111K Hold
415
0.2% 86
2022
Q2
$85K Hold
415
0.14% 100
2022
Q1
$87K Buy
415
+25
+6% +$5.44K 0.13% 106
2021
Q4
$93K Buy
+390
New +$100K 0.13% 106

Other funds holding BIIB

Norwood Financial's BIIB Position: Q1 2024 in Review

Norwood Financial held its Biogen (BIIB) position steady in Q1 2024 at 355 shares worth $76.5K. The position accounts for 0.11% of the portfolio, ranked #136.

Norwood Financial first reported a position in BIIB in Q4 2021 and has held it in 10 quarters since. The position peaked at $113K in Q1 2023. 955 funds tracked by Wall St. Rank hold BIIB as of Q1 2024.

  • Norwood Financial held 355 shares of Biogen worth $76.5K as of Q1 2024.
  • Norwood Financial left its Biogen share count unchanged in Q1 2024.
  • Biogen made up 0.11% of Norwood Financial's portfolio in Q1 2024, its #136 holding.
  • Norwood Financial first reported a position in Biogen in Q4 2021 and has held it in 10 quarters since.
  • Norwood Financial's Biogen position peaked at $113K in Q1 2023.
  • 955 funds tracked by Wall St. Rank held Biogen as of Q1 2024.

Based on Norwood Financial's 13F filing for Q1 2024, filed 16 Apr 2024.